Keudell Morrison Wealth Management Takes $514,000 Position in Kymera Therapeutics, Inc. $KYMR

Keudell Morrison Wealth Management acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 6,600 shares of the company’s stock, valued at approximately $514,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Eagle Health Investments LP purchased a new stake in Kymera Therapeutics during the fourth quarter worth about $10,606,000. PSP Research LLC acquired a new position in shares of Kymera Therapeutics in the fourth quarter valued at approximately $494,000. Larson Financial Group LLC grew its holdings in shares of Kymera Therapeutics by 36.9% in the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock valued at $83,000 after purchasing an additional 287 shares in the last quarter. TimesSquare Capital Management LLC acquired a new stake in Kymera Therapeutics during the 4th quarter worth approximately $14,776,000. Finally, Profund Advisors LLC lifted its holdings in Kymera Therapeutics by 48.1% during the 4th quarter. Profund Advisors LLC now owns 22,240 shares of the company’s stock worth $1,730,000 after buying an additional 7,227 shares in the last quarter.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $78.89 on Friday. Kymera Therapeutics, Inc. has a 12 month low of $28.06 and a 12 month high of $103.00. The firm has a market capitalization of $6.49 billion, a PE ratio of -22.10 and a beta of 2.06. The business’s fifty day moving average price is $83.18 and its 200 day moving average price is $78.58.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same period in the previous year, the business earned ($0.82) EPS. Kymera Therapeutics’s revenue for the quarter was up 55.5% on a year-over-year basis. As a group, equities analysts anticipate that Kymera Therapeutics, Inc. will post -3.34 EPS for the current year.

Insider Transactions at Kymera Therapeutics

In other news, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $90.26, for a total value of $2,707,800.00. Following the completion of the transaction, the chief executive officer owned 666,195 shares in the company, valued at approximately $60,130,760.70. This represents a 4.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Bruce N. Jacobs sold 7,576 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $88.93, for a total transaction of $673,733.68. Following the completion of the transaction, the chief financial officer directly owned 237,483 shares in the company, valued at $21,119,363.19. This trade represents a 3.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 383,734 shares of company stock valued at $32,454,902 over the last three months. 15.98% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on KYMR shares. Citigroup boosted their price target on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Piper Sandler lifted their target price on Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, February 26th. BTIG Research lowered their target price on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. UBS Group increased their price target on Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research report on Tuesday, March 3rd. Finally, Barclays lifted their price objective on Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research note on Tuesday, January 27th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $118.10.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.